ERBB3 and non-small cell lung carcinoma: EGFR-mutant NSCLC patients may have MET amplification prior to EGFR-TKI treatment, and EGFR-TKI exposure may increase the rate of MET amplification and activate the bypass pathway through transactivated ERBB3 [28].